Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 8/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | STK33 | Q9BYT3 | 1/20 | 0.37 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4310810 | 0.86 | ACHE (0.58) | ACHEF10ACKR3 | |
| SCHEMBL4306487 | 0.86 | ACHE (0.47) | ACHEF10ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL4316646 | 0.84 | ALDH1A1 (0.41) | ACHEF10ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL4303217 | 0.82 | STK33 (0.43) | ACHEF10ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL4307094 | 0.81 | F10 (0.45) | ACHEF10ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL4312090 | 0.81 | KMT2A (0.45) | ACHEF10ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL6220595 | 0.79 | ACHE (0.39) | ACHEALDH1A1DDB1CRBNMAP1LC3B | |
| SCHEMBL6216650 | 0.76 | ALDH1A1 (0.38) | ACHEF10ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL6402770 | 0.76 | ACHE (0.40) | ACHEF10ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL5783198 | 0.76 | ACHE (0.40) | ACHEF10ALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482472-B2 | Substituted isoindoles and their use | BAYER HEALTHCARE AG (DE) | 2009-01-27 | — | — | US | disclosed |
| US-7482472-B2 | Substituted isoindoles and their use | BAYER HEALTHCARE AG (DE) | 2009-01-27 | — | — | US | disclosed |
| US-7482472-B2 | Substituted isoindoles and their use | BAYER HEALTHCARE AG (DE) | 2009-01-27 | — | — | US | disclosed |
| US-20080039446-A1 | Substituted isoindoles and their use | BAYER HEALTHCARE AG (DE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039446-A1 | Substituted isoindoles and their use | BAYER HEALTHCARE AG (DE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039446-A1 | Substituted isoindoles and their use | BAYER HEALTHCARE AG (DE) | 2008-02-14 | — | — | US | disclosed |
| US-7189738-B2 | Substituted isoindoles and their use thereof | BAYER HEALTHCARE AG (DE) | 2007-03-13 | — | — | US | disclosed |
| US-7189738-B2 | Substituted isoindoles and their use thereof | BAYER HEALTHCARE AG (DE) | 2007-03-13 | — | — | US | disclosed |
| US-7189738-B2 | Substituted isoindoles and their use thereof | BAYER HEALTHCARE AG (DE) | 2007-03-13 | — | — | US | disclosed |
| EP-1414817-B1 | substituted isoindoles and the use thereof | BAYER HEALTHCARE AG (DE) | 2005-04-06 | — | — | EP | disclosed |
| US-20040215019-A1 | Substituted isoindoles and the e use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-10-28 | — | — | US | disclosed |
| EP-1414817-A1 | SUBSTITUTED ISOINDOLES AND E USE THEREOF | Bayer HealthCare AG (DE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003011858-A1 | SUBSTITUTED ISOINDOLES AND E USE THEREOF | BAYER HEALTHCARE AG (DE) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039446-A1 | Substituted isoindoles and their use | F2, F12, TFPI2 | ACHE 1206/4885F10 19/4885ALDH1A1 346/4885 |
| US-20040215019-A1 | Substituted isoindoles and the e use thereof | F2, F12, F5 | ACHE 1270/4885F10 14/4885ALDH1A1 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.